WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SELECT * FROM wp_clean_up_optimizer_ip_locations WHERE ip='3.238.250.73'

WordPress database error: [Table './shroom/wp_clean_up_optimizer_ip_locations' is marked as crashed and last (automatic?) repair failed]
SHOW FULL COLUMNS FROM `wp_clean_up_optimizer_ip_locations`

RVVTF – Shroom Investor 🍄

RVVTF

Revive Therapeutics Ltd.

32 views5 min read

Revive Therapeutics Submits Updated Briefing Package in Support of Upcoming Type C Meeting Granted by FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics
TORONTO, Jan. 19, 2023 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announces today that it has submitted the updated briefing package to the U.S. Food &... Read More...
592 views4 min read

Revive Therapeutics Ltd. Expands Life Offering to Quebec

Revive Therapeutics
TORONTO, Dec. 15, 2022 -- REVIVE THERAPEUTICS LTD. (CSE: RVV; OTCQB: RVVTF) (“Revive” or the “Company”) announces that it is expanding its previously announced private placement (see November 30, 2022 press release) to investors resident in the Province of Quebec. The Company is arranging a private placement of a minimum of $3 million and... Read More...
125 views3 min read

Revive Therapeutics Announces Update for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

Revive Therapeutics
TORONTO, Nov. 24, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it will submit the Type C meeting request package to the U.S. Food &a... Read More...
860 views4 min read

Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics
TORONTO, Oct. 14, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has finalized an amended protocol to the U.S. Food & Drug Admi... Read More...
560 views4 min read

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

Revive Therapeutics
TORONTO, Sept. 16, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on the Company’s Phase I/II clinical study of oral psiloc... Read More...
1140 views4 min read

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

Revive Therapeutics
Revive Therapeutics Ltd.TORONTO, Sept. 14, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has filed an amended protocol to the U.S.... Read More...
857 views4 min read

Revive Therapeutics Announces Publication of Research Data with Bucillamine in COVID-19

Revive Therapeutics
TORONTO, April 18, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced the publication of a scientific article evaluating the impact of medicati... Read More...
317 views4 min read

Revive Therapeutics Receives FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics
TORONTO, Feb. 15, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted Orph... Read More...
46 views5 min read

Revive Therapeutics Provides Update of Psilocybin Pharmaceutical Programs

Revive Therapeutics
IRB approval to initiate Phase 2 study for methamphetamine abuse disorders Advancing psilocybin oral thin film, microneedle patch and biosynthesis programs TORONTO, Jan. 17, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and ... Read More...
902 views4 min read

Revive Therapeutics Clarifies Status of Its Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics
Approximately 700 subjects participated in the enrollment periodExpected to begin subject enrollment in Turkey by mid-FebruaryExpected to complete enrollment in Q1-2022 TORONTO, Jan. 06, 2022 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the... Read More...
145 views5 min read

UPDATE — Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as b... Read More...
137 views5 min read

Revive Therapeutics Expands Bucillamine Research to Treat Omicron Variant and Adds Inflammatory Markers to FDA Phase 3 Clinical Trial

Revive Therapeutics
Expanding the potential of Bucillamine as an effective treatment for Omicron variant (B.1.1.529)Bucillamine shown to inhibit SARS-CoV-2 infection in vitro for the Delta variant (B.1.617.2)Adding inflammatory markers along with viral load testing to current Phase 3 clinical study for COVID-19 aiming to strengthen Bucillamine’s profile as b... Read More...
274 views4 min read

Revive Therapeutics Files for FDA Orphan Drug Designation for Bucillamine in the Prevention of Ischemia-Reperfusion Injury During Liver Transplantation

Revive Therapeutics
TORONTO, Nov. 23, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has filed an application with the U.S. Food and Drug Administrat... Read More...
946 views4 min read

Revive Therapeutics Announces Published Research Results on Bucillamine as Potential Inhibitor of SARS-CoV-2 Infection Delta Variant

Revive Therapeutics
TORONTO, Nov. 16, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a research study, titled “Thiol drugs decrease SARS-CoV-2 lung injury in ... Read More...
475 views5 min read

Revive Therapeutics Provides Update on Psychedelics Clinical Product Pipeline

Revive Therapeutics
Focusing on novel uses, production and delivery forms of psilocybin as a next generation solution for mental illness, substance abuse and neurological disordersAdvancing to FDA clinical studies for methamphetamine use disorder and stroke TORONTO, Aug. 10, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RV... Read More...
45 views4 min read

Revive Therapeutics Approved to Trade on the OTCQB Market

Revive Therapeutics
TORONTO, June 25, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF, FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that its common shares have been approved for trading on the OTCQB® Ma... Read More...
201 views4 min read

Revive Therapeutics Announces Research Collaboration with North Carolina State University for Natural Biosynthesis Enzymatic Platform To Develop Psilocybin

Revive Therapeutics
TORONTO, Jan. 14, 2021 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into a sponsored research agreement and an exclusive option to license ... Read More...
894 views4 min read

Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study

Revive Therapeutics
TORONTO, Dec. 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. John Fahy, MD, MSc, as a Scientific and Clinical advisor to the... Read More...
LOIM & A373 views5 min read

Revive Therapeutics Announces LOI to Acquire PharmaTher’s Psilocybin Program

Revive Therapeutics
TORONTO, Dec. 21, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated December 20... Read More...
803 views4 min read

Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor

Revive Therapeutics
TORONTO, Dec. 02, 2020 -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company... Read More...
362 views4 min read

Revive Therapeutics Announces Research Collaboration with PharmaTher for Development of Psilocybin in Cancer and Discovery of Novel Uses of Psychedelics

Revive Therapeutics
TORONTO, Nov. 18, 2020 -- Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce it has entered into an exclusive research collaboration agreement with PharmaTher Inc., a wholly-owned ... Read More...
62 views4 min read

Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin

Revive Therapeutics
TORONTO, Nov. 11, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide an update on its oral thin-film delivery system with psilocybin being developed under a... Read More...
725 views4 min read

Havn Life Sciences to Support the First Modern Psilocybin Depression Study in Germany With MIND Foundation

HAVN Life Sciences
The research will be led by Prof. Dr. Gerhard GrĂĽnder, the only confirmed scientist developing a study to work with psychedelics in Germany since the 1970sVANCOUVER, BC / ACCESSWIRE / October 30, 2020 / Havn Life Sciences Inc. (CNSX:HAVN)(FSE:5NP) (the "Company" or "Havn Life"), a biotechnology company focused on unlocking human potential... Read More...
579 views0 min read

Don’t miss out on your BIG thanksgiving party – iotum offers “Free-for-All” Thanksgiving Free Conference service for the holiday weekend

Revive Therapeutics
VANCOUVER, BC, Aug. 19, 2020 - The following issues have been halted by IIROC:Company: Revive Therapeutics Ltd.CSE Symbol: RVVAll Issues: YesReason: At the request of the Company Pending NewsHalt Time (ET): 11:59 AMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trad... Read More...
897 views8 min read

Revive Therapeutics Announces Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics
TORONTO, Sept. 29, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 c... Read More...
1126 views5 min read

Revive Therapeutics Provides Corporate Update on its Psychedelics Therapeutics Programs

Revive Therapeutics
TORONTO, Sept. 21, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to provide a corporate update on its psychedelics therapeutics programs specifically as it relates... Read More...
371 views6 min read

Revive Therapeutics Announces IRB Approval of US Expanded Access Treatment Program (Compassionate Use) for Bucillamine in COVID-19

Revive Therapeutics
TORONTO, Sept. 16, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s expanded access protocol (“EAP”) for compassionate use of Bucillam... Read More...
466 views8 min read

Revive Therapeutics Announces IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive Therapeutics
TORONTO, Aug. 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company’s Phase 3 clinical trial protocol to evaluate the safety and efficacy... Read More...
888 views8 min read

Revive Therapeutics Announces Submission of IRB Approval for Phase 3 Clinical Trial Protocol for Bucillamine in COVID-19

Revive Therapeutics
Revive to also explore FDA Expanded Access Program (Compassionate Use) for Bucillamine in COVID-19TORONTO, Aug. 26, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased ... Read More...
LOI1192 views5 min read

Revive Therapeutics Signs MOU with Attwill Medical Solutions for Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics
TORONTO, Aug. 14, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has signed a Memorandum of Understanding (“MOU”) with Attwill Medical Solutions... Read More...
420 views5 min read

Revive Therapeutics Advancing Drug Delivery Technology for Psychedelics

Revive Therapeutics
TORONTO, Aug. 11, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, US: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce, further to its press release of June 12, 2020, that under its sponsored research partn... Read More...
409 views6 min read

UPDATE – Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics
TORONTO, July 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV) (OTCQB: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company ... Read More...
1253 views6 min read

Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19

Revive Therapeutics
TORONTO, July 31, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with... Read More...
414 views4 min read

Revive Therapeutics Provides Update on Discussions with Health Canada in Pre-CTA Meeting

Revive Therapeutics
TORONTO, June 09, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the Company met with Health Canada in a Pre-Clinical Trial Application (“Pre-CTA”) meeting to ... Read More...
42 views5 min read

Revive Therapeutics Announces Filing of a Pre-CTA Meeting Request with Health Canada and Update on U.S. FDA IND Filing and Phase 3 Clinical Trial Design for Bucillamine in the Treatment of COVID-19

Revive Therapeutics
TORONTO, June 03, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has filed its Clinical Trial Application (“Pre-CTA”) with Health Canada and provides an upd... Read More...
1 views1 min read

Investor Announcement

Revive Therapeutics
TORONTO, April 03, 2020 -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE:RVV), a life sciences company, has learnt that buy recommendations and letters are being circulated in Germany. The Company, along with the Federal Financial Supervisory Authority of Germany (“BaFin”) suggests shareholders fully understand these materials... Read More...





Make smarter investment strategies
with in-depth news reports

Join our subscribers!